All Brands Owned by Novartis
Novartis owns 12 brands in our database. Browse the complete portfolio of Novartis subsidiaries and brands across various industries.
Company Type
public
Headquarters
Basel, Switzerland
Brand Portfolio
12 brands
Stock
SIX: NOVN
Filter by Category
Complete Brand Portfolio
Afinitor
Owned by Novartis
Prescription oncology medicine (everolimus) used to treat certain cancers and tuberous sclerosis complex, developed and marketed by Novartis AG.
Alcon
Owned by Novartis
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Cosentyx
Owned by Novartis
Prescription biologic medication for treating autoimmune diseases including psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and other inflammatory conditions.
Exelon
Owned by Novartis
Brand name for rivastigmine, a prescription cholinesterase inhibitor developed by Novartis for treating mild-to-severe Alzheimer's disease and Parkinson's disease dementia.
Gilenya
Owned by Novartis
Prescription immunosuppressant medication for treating relapsing-remitting multiple sclerosis, manufactured and marketed by Novartis.
Lamisil
Owned by Novartis
Over-the-counter antifungal medication for treating fungal infections including athlete's foot and toenail fungus, owned by Haleon plc.
Lucentis
Owned by Novartis
Prescription biologic medication for treating age-related macular degeneration and diabetic retinopathy, manufactured and marketed by Novartis.
Otrivin
Owned by Novartis
Over-the-counter nasal decongestant spray for relieving nasal congestion from colds and allergies, owned by Haleon plc.
Sandoz
Owned by Novartis
Independent global leader in generic and biosimilar pharmaceuticals, spun off from Novartis in October 2023 and publicly traded on the SIX Swiss Exchange (SDZ), reporting 9M 2025 net sales of USD 8.057 billion with biosimilars accounting for 27% of total sales.
Tasigna
Owned by Novartis
Prescription oncology medication for treating chronic myeloid leukemia, owned by Novartis, facing generic competition after its US patent expired in January 2024, with nilotinib generics now available in the market.
Theraflu
Owned by Novartis
Over-the-counter cold and flu relief medication combining multiple active ingredients for symptom relief, owned by Haleon, a British consumer health company spun off from GSK in 2022.
Voltaren
Owned by Novartis
Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owned by Haleon plc (LSE/NYSE: HLN) since its July 2022 spinoff from the GSK and Pfizer consumer health joint venture, with Voltaren growing mid-single digit in full-year 2025 supported by new format patches and Voltadexibu launches.
About Novartis
What does Novartis own?
Novartis owns a portfolio of innovative prescription medicines across oncology, immunology, cardiovascular, neuroscience, and ophthalmology. Key products include Cosentyx (inflammatory diseases), Entresto (heart failure), Kisqali (breast cancer), Kesimpta (multiple sclerosis), Leqvio (cholesterol), Zolgensma (gene therapy for spinal muscular atrophy), and Kymriah (CAR-T cell therapy). Novartis spun off its Sandoz generics division in 2023 and its Alcon eye care division in 2019.
Is Novartis publicly traded?
Yes, Novartis AG is listed on the SIX Swiss Exchange under ticker NOVN and on NASDAQ under ticker NVS (as American Depositary Receipts). The company has a broad institutional and retail shareholder base with no single controlling shareholder. Major institutional shareholders include Vanguard Group and BlackRock.
Who founded Novartis?
Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two of Switzerland's oldest pharmaceutical companies. Ciba-Geigy itself was formed through the 1970 merger of Ciba and Geigy, both founded in Basel in the 19th century. Sandoz was founded in 1886 in Basel. The 1996 merger was one of the largest corporate mergers in history at the time, valued at approximately $63 billion.
Where is Novartis headquartered?
Novartis AG is headquartered in Basel, Switzerland. Basel has been the center of the Swiss pharmaceutical industry for more than a century, and Novartis, Roche, and several other major pharmaceutical companies are headquartered in the city. Novartis operates manufacturing and research facilities in Switzerland, the United States, Germany, Spain, Italy, Japan, China, India, Singapore, and Brazil.
How many products does Novartis sell?
Novartis sells dozens of prescription medicines across multiple therapeutic areas. The company's growth portfolio is led by Cosentyx, Entresto, Kisqali, Kesimpta, Leqvio, Zolgensma, and Kymriah. Novartis has a pipeline of more than 150 projects in clinical development across its therapeutic focus areas. The company sells products in more than 140 countries worldwide.
Who owns Novartis?
Novartis AG is publicly traded on the SIX Swiss Exchange and NASDAQ with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. The Novartis Foundation for Employee Participation holds a significant stake. Major institutional shareholders include Vanguard Group and BlackRock. Vas Narasimhan serves as CEO and Joerg Reinhardt chairs the board.
Stock Information
Competitors to Novartis
No competing brands found in the same categories. This could be because Novartisoperates in unique market segments or we're still building our competitor database.
Novartis Brand Portfolio Overview
Novartis maintains a diverse portfolio of 12 brands across multiple industries. This comprehensive brand portfolio demonstrates the company's market presence and strategic business units.
Brand Portfolio by Industry:
- Healthcare & Pharmaceuticals: 12 brands
For consumers and researchers interested in corporate ownership structures, understanding which brands are owned by Novartisprovides valuable insights into market dynamics, product relationships, and corporate strategy.
Explore More
Jobs at Novartis
Latest News About Novartis
Articles About Novartis
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Monthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.
Monthly M&A Roundup: June 2026 Brand Ownership Changes
June 2026's biggest brand ownership moves: Berkshire Hathaway agreed to buy Taylor Morrison for $6.8B, GSK struck a $10.6B deal for Nuvalent, CRH acquired Arcosa for $8.5B, and Qualcomm agreed to buy AI startup Modular for $3.92B. Full breakdown of every major deal.